Internal Reference Number: FOI_9518
Date Request Received: 06/07/2026 00:00:00
Date Request Replied To: 21/07/2026 00:00:00
This response was sent via: By Email
Request Summary: Oncology
Request Category: Researcher
| Question Number 1: How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib | |
| Answer To Question 1: • Atezolizumab (Tecentriq)less than 5 • Durvalumab (Imfinzi)less than 5 • Nivolumab (Opdivo) 0 • Pembrolizumab (Keytruda) 0 • Chemotherapy Less than 5 • Radiotherapy not provided at SFT • Chemotherapy AND Radiotherapy - radiotherapy not provided at SFT • Osimertinib 0 | |
| Question Number 2: How many patients has your Trust treated in total in the past 3 months for • Stage 2 Non-Small Cell Lung Cancer • Stage 3 Non-Small Cell Lung Cancer | |
| Answer To Question 2: • Stage 2 Non-Small Cell Lung Cancer less than 5 • Stage 3 Non-Small Cell Lung Cancer less than 5 | |
| Question Number 3: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab • Pembrolizumab monotherapy • Pembrolizumab monotherapy (subcutaneous injection formulation only) • Pembrolizumab with chemotherapy • Pembrolizumab with chemotherapy (subcutaneous injection formulation only) • Nivolumab • Osimertinib • Durvalumab • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 3: • Atezolizumab less than 5 • Pembrolizumab monotherapy 0 • Pembrolizumab monotherapy (subcutaneous injection formulation only) 0 • Pembrolizumab with chemotherapy 0 • Pembrolizumab with chemotherapy (subcutaneous injection formulation only) 0 • Nivolumab 0 • Osimertinib 0 • Durvalumab less than 5 • Chemotherapy less than 5 • Radiotherapy not provided at SFT • Chemotherapy + Radiotherapy radiotherapy not provided at SFT | |
| Question Number 4: How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy | |
| Answer To Question 4: • Chemotherapy less than 5 • Radiotherapy not provided at SFT • Chemotherapy + Radiotherapy - radiotherapy not provided at SFT | |
| Question Number 5: How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Durvalumab | |
| Answer To Question 5: 0 | |
| To return to the list of all the FOI requests please click here |
Our staff at 91Ó°ÊÓ District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
